Abstract |
Several short- and long-term studies conducted in Europe/North America have demonstrated good efficacy and tolerability of 600-1800 mg gabapentin enacarbil (GEn). However, no studies have evaluated the efficacy of long-term treatment with GEn in Asian patients. Therefore, the objective of this study was to evaluate the efficacy and safety of long-term treatment with GEn in Japanese patients with restless legs syndrome (RLS) in a multicenter open-label study. RLS patients aged 20-80 years were allocated to receive oral GEn 1200 mg/day for a treatment period of 52 weeks. International Restless Legs Syndrome Scale (IRLS) score, investigator- and patient-rated Clinical Global Impression (CGI) scores, Pittsburgh Sleep Quality Index (PSQI) total scores and subscores, and short form (SF)-36 subscores were assessed, and adverse events (AEs) were monitored. In 181 patients (mean age, 54.9±12.2 years; BMI, 23.0±2.6 kg/m²) IRLS score decreased from 24.4±0.4 at baseline to 6.3±0.6 at week 52, with a reduction of -18.0±0.6. The IRLS responder rate was 80.3% at week 52. ICGI and PCGI responder rates were 87.1% and 87.1%, respectively. PSQI and SF-36 also showed significant improvements. AEs were reported in 96.2% of patients but remained mild-to-moderate in nearly all the cases. Serious AEs occurred in 1.6%. Dizziness and somnolence were noted in 46.2% and 41.2% of patients, respectively, and mostly occurred during the first 4 weeks. No episodes of augmentation were reported. In conclusion, long-term treatment with GEn improved RLS symptoms as well as investigator- and patient-reported outcomes in Japanese patients with moderate-to-severe RLS, with an acceptable safety profile. Randomized, double-blind, placebo/active-controlled trials are desirable to confirm these preliminary results.
|
Authors | Yuichi Inoue, Naohisa Uchimura, Kenji Kuroda, Koichi Hirata, Nobutaka Hattori |
Journal | Progress in neuro-psychopharmacology & biological psychiatry
(Prog Neuropsychopharmacol Biol Psychiatry)
Vol. 36
Issue 2
Pg. 251-7
(Mar 30 2012)
ISSN: 1878-4216 [Electronic] England |
PMID | 22036917
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2011 Elsevier Inc. All rights reserved. |
Chemical References |
- 1-(((alpha-isobutanoyloxyethoxy)carbonyl)aminomethyl)-1-cyclohexaneacetic acid
- Anticonvulsants
- Carbamates
- gamma-Aminobutyric Acid
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Anticonvulsants
(adverse effects, therapeutic use)
- Asian People
- Carbamates
(adverse effects, therapeutic use)
- Female
- Humans
- Male
- Middle Aged
- Quality of Life
- Restless Legs Syndrome
(drug therapy)
- Severity of Illness Index
- Sleep Wake Disorders
(chemically induced, drug therapy)
- Time Factors
- gamma-Aminobutyric Acid
(adverse effects, analogs & derivatives, therapeutic use)
|